About the Company

A.P. Pharma, Inc. (NASDAQ: APPA) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma received a Complete Response Letter on the APF530 NDA in March 2010 and is in the process of preparing a resubmission responsive to the deficiencies listed in the Complete Response Letter. The Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems.

Recent Press Releases

05/26/10 - A.P. Pharma Announces Changes in Management and Hires Leading Consulting Practice to Lead FDA Review Process

05/20/10 - A.P. Pharma Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule

05/17/10 - A.P. Pharma Announces First Quarter 2010 Financial Results

 

More Releases >>